US FDA approves a new treatment for phenylketonuria
The US Food and Drug Administration (FDA) has approved Palynziq (pegvaliase-pqpz) for adults with phenylketonuria, a rare and serious genetic disease. Patients with PKU are born with an inability to break down phenylalanine, an amino acid present in protein-containing foods and high-intensity sweeteners used in a variety of foods and beverages.
To continue reading this article
Continue reading your article with a eMediNexus account.